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Context: GLIS3 (Gli-similar 3) is a member of the GLI-similar zinc finger protein family encoding for a nuclear protein with five C2H2-type zinc finger domains. The protein is expressed early in embryogenesis and plays a critical role as both a repressor and activator of transcription. Human GLIS3 mutations are extremely rare. 

Objective: To determine the phenotypic presentation of 12 patients with a variety of GLIS3 mutations.

Methods: GLIS3 gene mutations were sought by PCR amplification and sequence analysis of exons 1–11. Clinical information was provided by the referring clinicians and subsequently using a questionnaire circulated to gain further information.

Results: We report the first case of a patient with a compound heterozygous mutation in GLIS3 who did not present with congenital hypothyroidism. All patients presented with neonatal diabetes with a range of insulin sensitivity. Thyroid disease varied between patients. Liver and renal disease was common with liver dysfunction ranging from hepatitis to cirrhosis and cystic dysplasia was the most common renal manifestation. We describe new presenting features in patients with GLIS3 mutations including craniosynostosis, hiatus hernia, atrial septal defect, a splenic cyst and choanal atresia, and confirm further cases with sensioneural deafness and exocrine pancreatic insufficiency. 








Permanent neonatal diabetes (PND) and congenital hypothyroidism can result from a number of genetic mutations. Mutations in KCNJ11 and ABCC8 genes, encoding the Kir6.2 and SUR1 subunit of the pancreatic ATP-sensitive potassium (KATP) channel involved in regulation of insulin secretion, account for about half of the PND cases 1. Mutations in the INS gene leading to the disruption insulin synthesis also result in PND 2. Further possible candidate genes for PND include GCK, PDX1, GATA6, NEUROD1, NEUROG3, NKX2-2, IER3IP, PTF1A, HNF1B, RFX6 and MNX. Syndromes that incorporate PND include IPEX syndrome (FOXP3), Wolcott-Rallison syndrome (EIF2AK3) and pancreatic agenesis (PDX1, PTF1A, GATA6, GATA4) 1 3. Mutations in TSHR, PAX8, NKX2-1, FOXE1 and NKX2-5 lead to congenital structural thyroid abnormalities  and thyroid dyshormonogenesis derives from mutations in DUOX2, SLC5A5, TG, TPO, and DEHAL1 4. Mutations in GLIS3 (Gli-similar 3) result in the concomitant presentation of PND and congenital hypothyroidism. GLIS3, a member of the GLI-similar zinc finger protein family encoding for a nuclear protein with five C2H2-type zinc finger domains, maps to chromosome 9p24.3-p23 (OMIM#610192)5. The protein is expressed early in embryogenesis and plays a critical role as both a repressor and activator of transcription5 6. It is specifically involved in the development of pancreatic beta cells, the thyroid, eye, liver and kidney although tissue expression occurs to a lesser extent in the heart, skeletal muscle, stomach, brain, adrenal gland and bone 7 8. In 2003 Taha et al 9 described a consanguineous Saudi Arabian family in which 2 of 4 siblings had permanent neonatal diabetes associated with intrauterine growth retardation (IUGR), congenital hypothyroidism, facial anomalies, congenital glaucoma, hepatic fibrosis, and polycystic kidneys, described as NDH (Neonatal Diabetes and Hypothyroidism) Syndrome 9. A third child from that family consequently died of the same condition 10. Genome wide linkage analysis and sequencing of candidate genes performed on this family by Senee et al 8 in 2006 identified a homozygous frameshift mutation (c.1873dupC, previously reported as 2067insC) in the GLIS3 gene which is likely to result in transcript degradation by nonsense mediated decay 6. Both children with this mutation died in infancy. Senee et al 8 described two further families with mutations in GLIS3. The first harboured a homozygous 426-kb deletion, which encompassed the SLC1A1 gene and part of GLIS3. The affected offspring in the other family carried a homozygous 149-kb deletion that included a portion of GLIS3 as well; the region common to both deletions mapped to the known start codon of GLIS3. Patients in these two families presented a milder phenotype. Variation in the GLIS3 phenotype has been attributed to the tissue-specific expression of variable length transcripts derived from the 11 exon GLIS3 gene. Absence of pancreatic and thyroid GLIS3 transcripts in the 2 families with deletions resulted in neonatal diabetes and hypothyroidism and absence of an eye specific transcript in one family resulted in congenital glaucoma. The absence of renal and liver abnormalities was attributed to the unaltered expression of liver and renal specific transcripts. More recently an extended phenotype associated with mutations in GLIS3 has been reported including skeletal abnormalities and exocrine pancreatic dysfunction11. Given the rarity of this condition, further information relating genotype to phenotypic manifestation is required.





The study was conducted in accordance with the Declaration of Helsinki principles with informed parental consent given on behalf of children. Clinical information was provided by the referring clinicians via a neonatal diabetes request form (available at www.diabetesgenes.org), from clinical notes and subsequently using a questionnaire circulated to referring clinicians to gain further information. 

Genetic analysis
GLIS3 gene mutations were sought by PCR amplification (primer sequences available on request) and sequence analysis of exons 1–11 by comparison with the reference sequence NM_001042413. Exon 1 is non-coding (the 5’ untranslated) and the start codon is located within exon 2. 
The effect of coding variants on the protein was investigated in silico using the bioinformatic tool ALAMUT (Interactive Biosoftware, Rouen, France). When failure of PCR amplification occurred, suggesting a homozygous deletion, parental samples were investigated by real-time quantitative PCR on an ABI 7900 (TaqMan assay with SYBR Green detection) and the copy number of exons 1–11 was determined by the 2-ΔΔCt method.





Table 1 describes the nucleotide and predicted protein changes of the GLIS3 mutations identified in our case series. Deletions of one or more of the 11 exons of GLIS3 were observed in the majority of patients. Patients 1, 5 and 10 harbour missense mutations (p.Arg589Trp, p.Cys536Trp and p.His561Tyr respectively) affecting highly conserved amino acids located in the DNA binding domain and so are likely to be pathogenic thus severely affecting the function of the GLIS3 protein. Patient 1 is the first patient reported being compound heterozygote for two mutations in GLIS3 (a deletion and a missense mutation). Patients 3a and 3b are siblings. Figure 1 provides a schematic representation of GLIS3 showing the mutations described in our patient population.
The clinical features of all the patients are summarised in table 2. All but two of the patients in our case series remain alive to date and patient 1 is the first patient with a GLIS3 mutation to survive into adulthood (aged 36). Patient 6 died from hepatic failure with marked portal hypertension and esophageal variceal bleeding, and Patient 9 died of overwhelming measles sepsis and multi-organ failure at 6 months of age. Nine patients in our cohort were born to parents who were first cousins. Patient 3 who was born to apparently not related parents was previously described by Dimitri et al 11. In this case series we describe another child with a GLIS3 mutation born to Caucasian parents who are not related (patient 1) and the sibling of patient 3a (patient 3b). A homozygous deletion was confirmed in patient 6; however, consanguinity was denied by the patient’s parents.

PND was the only consistent feature of all our patients with GLIS3 mutations. Age at diagnosis ranged from birth to 23 days. All patients are insulin treated. Patients were initially commenced on insulin at 0.4-2.0 units/kg/24 hours (patient 4 required 2.0 units/kg/24 hours) demonstrating a range of insulin sensitivity. Patient 11 had a high insulin sensitivity leading to recurrent hypoglycaemic episodes with very small doses of insulin. Others had labile blood glucose (patients 3a and 3b) and one patient  clinically demonstrated insulin resistance particularly during periods of illness (patient 2). In the first year of life patient 2 required 0.5 to 0.7 units/kg insulin per day. However, during times of intercurrent illness doses of insulin at three to four times her normal requirement were required to achieve normoglycaemia. Despite erratic blood glucose control with periods of insulin resistance, her glycosylated haemoglobin at 1 year of age was 7.8% (62.0 mmol/mol).

Apart from patient 1, all patients were diagnosed with congenital hypothyroidism. This is a cardinal feature of the NDH syndrome previously described in all patients with GLIS3 mutations8 9. Although all patients with congenital hypothyroidism presented during the first week of life, the pattern of thyroid disease was variable. Patients 2, 3a and 3b had an elevated TSH that was resistant to treatment with thyroxine as previously described 11. Similarly, patients 7 and 11 had very high TSH that did not reduce to normal limits with levothyroxine therapy despite normalising the free T4. In these three patients thyroid anatomy was normal on ultrasonography. In contrast patient 4 presented with congenital hypothyroidism due to athyreosis and responded to levothyroxine at a starting dose of 28 micrograms/kg/day. In patients 5 and 8, thyroid ultrasonography was not performed. However, initial levothyroxine requirements were 24 micrograms/kg/day and 15 micrograms/kg/day respectively. Patient 8 had fluctuating levels of TSH (20-30 mIU/L) in the first year of life despite normal levels of free T4 which have since normalised. Patients 6 and 10 had normal thyroid anatomy on ultrasonography, and in comparison with other patients with GLIS3 mutations, the TSH responded appropriately to conventional doses of levothyroxine with an appropriate increase in levothyroxine dose with age. Notably, the post-mortem examination of the thyroid gland in patient 6 demonstrated paucity of colloid as well as extensive perifollicular and interstitial fibrosis explaining the need for thyroxine despite apparently normal thyroid anatomy on ultrasonogrpahy. 

Liver disease was documented in seven of our twelve patients. The hepatic dysfunction   presented concomitantly with renal abnormalities and ranged from hepatitis (patients 3b and 4) to hepatic fibrosis and cirrhosis (patients 2, 3a, 6, 7, 9 and 10). Nine patients have anatomical kidney changes. Of these, seven children showed variable renal cystic dysplasia ranging from an isolated cyst observed in patient 10, bilateral calyceal calcification in patient 11, to extensive cystic renal dysplasia (patients 2, 3a, 3b, 4, 9), (figure 2). Patient 7 lacks renal corticomedullary differentiation and renal ultrasonography in patient 6 demonstrated bilateral renal enlargement with no cystic changes. 

Patient 2 was the first patient to be described with skeletal manifestations secondary to a mutation in GLIS3. She presented with osteopenia, significantly delayed rib fracture healing and a marked thoracolumbar scoliosis (figure 3a and 3b). At 4 months of age, parathyroid hormone (PTH) level was 62.6 ng/l (11–35) with a 25-hydroxyvitamin D of 34.6 nmol/l (50–90). Serum calcium, phosphate and bone alkaline phosphatase concentrations measured 2.56 (2.13–2.72), 2.27 (1.10–2.40) and 297.3 (9–28) mmol/l respectively. Despite normalisation of the PTH and vitamin D level following treatment with ergocalciferol and calcium, the patient sustained a further rib fracture on the left side 11. Patient 5 was also reported to have skeletal abnormalities with prominent right 6th and 7th ribs but normal bone biochemistry. Patient 6 is the first patient with a mutation in GLIS3 to have sagittal craniosynostosis requiring surgical intervention. This patient initially manifested with mild hypocalcaemia in the 2nd month of life (7.8 mg/dl; normal range 8.7-10.1 mg/dl) which subsequently normalised without treatment. Patient 8 was osteopenic by 6 months and despite vitamin D supplementation her 25OH vitamin D3 level was 33.5nmol/l at 6 weeks of age. Adjusted serum calcium in this patient was 2.0 mmol/l in the first week of life and subsequently normalised to 2.5 mmol/l by 12 days of age without calcium replacement. Alkaline phosphatase peaked at 3 months to 2100 U/L but had normalised by 2 years of age. No fractures were identified in patient 8. 

Malabsorption due to exocrine pancreatic insufficiency as demonstrated by low faecal elastase was a feature in patients 2, 3a, 3b and 7 in our case series. These four patients have been treated with pancreatic enzyme supplementation. We report the first patient with a GLIS3 mutation to present with a splenic cyst (patient 3b).
Developmental delay and IUGR were common features in our patient cohort. Only 4 out of 12 of our patients were diagnosed with congenital glaucoma although there was no clear relationship between the ocular presentation and the GLIS3 exon affected as suggested by Senee et al4. 






The variability in phenotype observed between our patients and others 8 has been attributed to the differential expression of multiple GLIS3 transcripts. Two major transcripts have previously been described – 7.5 kb and smaller (0.8–2.0 kb); the 7.5-kb transcript is strongly expressed in pancreas, thyroid and kidney with smaller transcripts predominantly expressed in liver, kidney, heart and skeletal muscle 8. Thus mutations in GLIS3 have the potential to cause widespread disruption. Previously described severely affected individuals with mutations in GLIS3 appear to have total loss of function of the gene 8. For severely affected patients with deletions it is likely that the mutated transcripts undergo nonsense-mediated decay and little or no protein is produced. Patient 1 is the first case described with biallelic GLIS3 mutations who has not been diagnosed with congenital hypothyroidism and she has a milder phenotype than other patients in the cohort. She is a compound heterozygote for a whole-gene deletion and a missense mutation in exon 5 (p.Arg589Trp). We thus speculate that the missense mutation may be a hypomorphic change resulting in a mutated protein possessing some residual function. 

The cardinal feature in all our patients was the diagnosis of neonatal diabetes in the first weeks of life and the concomitant presence of IUGR may reflect significant intrauterine insulin deficiency. GLIS3 plays a key role in pancreatic development, particularly in the embryogenesis of β-cells which explains why our patients and others with GLIS3 mutations to date have presented with PND 11. GLIS3 interacts with key regulatory genes in pancreatic embryogenesis including ONECUT1 and NEUROGENIN3 (NEUROG3) 13-15. GLIS3 expression also persists beyond the embryonic period promoting beta cell proliferation and regulating insulin gene expression through binding to GLI-RE on the INS gene 16.  Therefore, the variation in insulin sensitivity between patients (and mutations) may relate to the impact of the mutation on the nuclear localisation, GLI-binding element activity, transactivation, pancreatic development, subsequent beta-cell proliferation, and remnant endogenous insulin production. In humans GLIS3 has been identified as a susceptibility locus for the risk of type 1 and 2 diabetes. 17 18 The significant insulin requirements observed during periods of illness in our more severely affected patients may also suggest a possible role of GLIS3 on end-organ response to insulin, possibly at the level of the insulin receptor.  However a large difference in the insulin sensitivity was observed in patients with the same mutation in our cohort (patient 2 and patient 11). This suggests that other genetic factors might influence the insulin response in these patients. Initially abnormalities in the pancreas in patients with GLIS3 mutations were thought to be limited to beta-cells. However, GLIS3 transcripts are not only highly expressed in pancreatic beta cells, but also to a lesser degree in pancreatic acini. The presence of exocrine pancreatic dysfunction in patients 2, 3a, 3b and 7 in our series suggests that exocrine pancreatic involvement may be more extensive than previously described 8. The presence of pancreatic cystic change in patients 3a and 3b supports the previous observations that GLIS3 is important in the development and maintenance of pancreatic ducts 15.

The spectrum of structural thyroid abnormalities including athyreosis, glandular hypoplasia, and normal thyroid anatomy with lack of normalisation of TSH following therapy with thyroxine in infancy demonstrates a broad range of thyroid dysfunction resulting from mutations within the same gene. A recent post-mortem in patient 6 demonstrated paucity of colloid as well as extensive perifollicular and interstitial fibrosis despite initially normal thyroid ultrasonogrpahy. No explanation for this variation has been offered to date although a similar phenotypic variability is also observed in patients with mutations in PAX8 and NKX2-1 (TTF1/NK2 homeobox-1 or thyroid transcription factor1), involved in thyroid cell differentiation and proliferation and subsequent expression of genes encoding for thyroglobulin, thyroid peroxidase, thyrotropin receptor (TSHR) and the sodium–iodide symporter 19-21. However, despite these phenotypic similarities there is no evidence for conserved GLI transcription binding sites in the PAX8, NKX2-1 or TSHR flanking gene sequences. Further in-vitro work is required to determine whether GLIS3 works upstream of genes in pathways regulating thyroid development, hormonogenesis and end organ response to T4. The failure of suppression of TSH following thyroxine supplementation in some patients suggests an additional thyroid hormone resistance. Further work is required to understand the role of GLIS3 in thyroid hormone activity. 

As previously described in patients with GLIS3 mutations 8, the majority of our patients presented renal parenchymal disease, primarily renal cystic dysplasia. However, some patients with mutations in GLIS3 did not develop renal disease. Whilst the variation in renal manifestations may be mutation related, out of three related patients with a homozygous insertion (2067insC) leading to a frameshift and likely degradation of the transcript reported by Senee et al 8, only two had renal cystic dysplasia. Similarly, the manifestations of hepatic disease varied between patients. GLIS3 contains twenty-nine known putative transcription start sites across the 11 exon gene resulting in variable length transcripts. Larger (7.5 kb) and smaller (0.8-2.0 kb) transcripts are expressed in the kidney and smaller (0.8-2.0 kb) transcripts are expressed in the liver 8. The variable presentation of hepatic and renal disease therefore may be related to the relative qualitative and quantitative expression of tissue transcripts and the encoded proteins in individual patients, or alternatively the variation in the expression of regulatory transcripts. 

The majority of patients described to date with GLIS3 mutations also present dysmorphic features 8. In our cohort dysmorphic features were seen in nine out of the twelve patients. GLIS3 is expressed during embryonic face development which may help in part to explain the dysmorphic facial features observed in these patients.5 Congenital glaucoma was observed in patients 6, 7, 10 and 11 in our cohort. In mouse models, Glis3 is expressed in a dynamic pattern during eye development, initially in the dorsal optic vesicle and subsequently in the lens and the retina which supports the presentation of glaucoma in our patients and previous patients with GLIS3 mutations5. However from our cohort we were unable to ascribe a specific exon relating to the eye disease.

Skeletal manifestations were first described in 2011 11 in a patient with a GLIS3 mutation presenting multiple rib fractures with persistence in callus formation and scoliosis associated with a deletion in exons 1–2. The persistence in callus formation suggests a defect in bone remodelling either due to dysfunctional osteoblast signalling to osteoclasts or reduced osteoclastic bone reabsorption. Milder skeletal abnormalities (prominence of the left ribs) were observed in patient 5 (table 1) who carries a missense mutation in GLIS3 and osteopenia in patient 7 who also has a missense mutation in exon 4. Patient 6 presented with craniosynostosis which is a novel presentation in the GLIS3 phenotype. Recent evidence suggests a role of GLIS3 in osteoblast differentiation by the upregulation of FGF18 7 22. A reduction or absence in FGF18 results in delayed bone mineralisation secondary to diminished osteoblast terminal differentiation and proliferation. The expression of GLIS3 and WWTR1 overlap in the kidney and mutations in both genes results in renal cystic dysplasia with a high glomerular cystic load 23 24. Similarly, WWTR1 and GLIS3 have a stimulatory role in osteogenesis while inhibiting adipogenesis 7. WWTR1 interacts with GLIS3 to enhance its transcriptional activity by acting as a co-activator. The C-terminus of GLIS3 is fundamental for this action 24.  Thus, GLIS3 mutations that affect the C-terminal domain abolish the interaction between these genes which may in part explain the concomitant renal and skeletal manifestations seen in human GLIS3 mutations. 

We previously reported the first patient with a GLIS3 mutation to present with sensioneural deafness (patient 3a) 11. We now report this finding in the sibling of patient 3a (3b) and another unrelated child (Patient 8) with a frameshift mutation at exon 4. This mutation will introduce a premature stop codon and the subsequent transcript will be degraded in a similar way to deletions in GLIS3. As functionally this mutation has a similar effect to deletions, we are unable to associate the hearing defect with a specific exon although exon 4 is affected in all 3 patients. For patients severely affected by GLIS3 mutations, developmental delay and learning difficulties are common features. GLIS3 is known to be expressed in brain tissue during embryogenesis but there is little evidence to date connecting GLIS3 with brain development. Only one study to date using GWAS of cerebrospinal fluid tau levels to identify risk variants for Alzheimer's disease, has identified GLIS3 as a significant locus for the development of Alzheimer’s disease 25. Further work in this area is required to understand how GLIS3 may alter cerebral embryogenesis and maturation. 

In one of our families (patient 2) and a family reported by Senee et al8, the deletion encompassed also the gene encoding the neuronal/epithelial high-affinity glutamate transporter (solute carrier family 1  - SLC1A1). SLC1A1 is principally expressed in neurons, kidney and small intestine. Mutations in SLC1A1 are thought to cause dicarboxylicamino aciduria 26 and have been associated with psychiatric disorders including psychosis, obsessive compulsive disorder and neuronal degeneration 27 28.

We have presented an extended spectrum of clinical features in relation to patients with mutations in the GLIS3 gene. Our current study has focused on the clinical manifestations of patients with these mutations, and further in-vitro work is required to test the GLIS3 missense variants functionally in biological models. 

In summary, patients presenting with mutations in GLIS3 characteristically present with neonatal diabetes with variable insulin sensitivity and congenital hypothyroidism due to a range of underlying causes. Whilst mutations in GLIS3 are more common in consanguineous pedigrees, we report two patients with GLIS3 mutations from apparently unrelated parents. We also report the first patient with compound heterozygous mutations in GLIS3 with preservation of thyroid function, who is also the first patient reported with a GLIS3 mutation to survive into adulthood. Hepatic and renal disease is common in the patients in our cohort but the presentation is variable. We report new findings within the GLIS3 phenotype including cardiac disease, hiatus hernia, sagittal craniosynostosis, splenic cystic change and choanal atresia further extending the spectrum of abnormalities associated to GLIS3 mutations and providing novel insights into the role of GLIS3 in human physiological development. We report further patients presenting with exocrine pancreatic insufficiency and sensioneural deafness. All but two of the patients within our cohort are still alive suggesting that even patients with a severe GLIS3 phenotype associated may have a longer life expectancy than originally described.
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(a) Anteroposterior chest x-ray of patient 2 performed on day 101 demonstrating thoracolumbar scoliosis and left rib fractures located on ribs 7,8 and 9

(b) Anteroposterior chest x-rays performed on day 412 demonstrating worsening thoracolumbar scoliosis and persistence of callus formation in left ribs 7,8 and 9 with a new fracture at left rib 6.
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